Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Commission Determination Not To Review an Initial Determination Granting an Unopposed Motion of Complainants Resmed Corp., Resmed Inc., and Resmed Ltd. To Amend the Complaint, 76858-76859 [2013-30115]
Download as PDF
76858
Federal Register / Vol. 78, No. 244 / Thursday, December 19, 2013 / Notices
Act of 1930 (19 U.S.C. 1671b(a) and
1673b(a)) (the Act), that there is a
reasonable indication that an industry
in the United States is materially
injured by reason of imports from China
of 1,1,1,2-Tetrafluoroethane, provided
for in subheading 2903.39.20 of the
Harmonized Tariff Schedule of the
United States, that are alleged to be sold
in the United States at less than fair
value (‘‘LTFV’’), and that are allegedly
subsidized by the Government of China.
emcdonald on DSK67QTVN1PROD with NOTICES
Commencement of Final Phase
Investigations
Pursuant to section 207.18 of the
Commission’s rules, the Commission
also gives notice of the commencement
of the final phase of its investigations.
The Commission will issue a final phase
notice of scheduling, which will be
published in the Federal Register as
provided in section 207.21 of the
Commission’s rules, upon notice from
the Department of Commerce
(Commerce) of affirmative preliminary
determinations in the investigations
under sections 703(b) or 733(b) of the
Act, or, if the preliminary
determinations are negative, upon
notice of affirmative final
determinations in those investigations
under sections 705(a) or 735(a) of the
Act. Parties that filed entries of
appearance in the preliminary phase of
the investigations need not enter a
separate appearance for the final phase
of the investigations. Industrial users,
and, if the merchandise under
investigation is sold at the retail level,
representative consumer organizations
have the right to appear as parties in
Commission antidumping and
countervailing duty investigations. The
Secretary will prepare a public service
list containing the names and addresses
of all persons, or their representatives,
who are parties to the investigations.
Background
On October 22, 2013, a petition was
filed with the Commission and
Commerce by Mexichem Fluor Inc., St.
Gabriel, LA, alleging that an industry in
the United States is materially injured
or threatened with material injury by
reason of LTFV and subsidized imports
of 1,1,1,2-Tetrafluoroethane from China.
Accordingly, effective October 22, 2013,
the Commission instituted
countervailing duty investigation No.
701–TA–509 and antidumping duty
investigation No. 731–TA–1244
(Preliminary).
Notice of the institution of the
Commission’s investigations and of a
public conference to be held in
connection therewith was given by
posting copies of the notice in the Office
VerDate Mar<15>2010
16:41 Dec 18, 2013
Jkt 232001
of the Secretary, U.S. International
Trade Commission, Washington, DC,
and by publishing the notice in the
Federal Register of October 28, 2013 (78
FR 64243). The conference was held in
Washington, DC, on November 12, 2013,
and all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission transmitted its
determinations in these investigations to
the Secretary of Commerce on December
13, 2013. The views of the Commission
are contained in USITC Publication
4444 (December 2013), entitled 1,1,1,2Tetrafluoroethane from China,
Investigation Nos. 701–TA–509 and
731–TA–1244 (Preliminary).
Dated: December 13, 2013.
By order of the Commission.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–30159 Filed 12–18–13; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–890]
Certain Sleep-Disordered Breathing
Treatment Systems and Components
Thereof; Commission Determination
Not To Review an Initial Determination
Granting an Unopposed Motion of
Complainants Resmed Corp., Resmed
Inc., and Resmed Ltd. To Amend the
Complaint
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 4) of the presiding
administrative law judge granting an
unopposed motion of complainants
Resmed Corp., Resmed Inc., and
Resmed Ltd. to amend the complaint in
the above-captioned investigation.
FOR FURTHER INFORMATION CONTACT:
James A. Worth, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
205–3065. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
may also be obtained by accessing its
Internet server (https://www.usitc.gov).
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on Friday, August 23, 2013, based on a
complaint filed on July 19, 2013, on
behalf of ResMed Corp. of San Diego,
California; ResMed Inc. of San Diego,
California; and ResMed Ltd. of Bella
Vista, Australia (collectively,
‘‘Complainants’’). 78 FR 52563 (August
23, 2013). The complaint alleged
violations of Section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, in the sale for importation,
importation, or sale within the United
States after importation of certain sleepdisordered breathing treatment systems
and components thereof by reason of
infringement of one or more of claims
32–37, 53, 79, 80, and 88 of U.S. Patent
No. 7,997,267; claims 1–7 of U.S. Patent
No. 7,614,398; claim 1 of U.S. Patent
No. 7,938,116; claims 30, 37, and 38 of
U.S. Patent No. 7,341,060; claims 1, 3,
5, 11, 28, 30, 31, and 56 of U.S. Patent
No. 8,312,883; claims 13, 15, 16, 26–28,
51, 52, and 55 of U.S. Patent No.
7,926,487; claims 1, 3, 6, 7, 9, 29, 32, 35,
40, 42, 45, 50, 51, 56, 59, 89, 92, 94, and
96 of U.S. Patent No. 7,178,527; and
claims 19–24, 26, 29–36, and 39–41 of
U.S. Patent No. 7,950,392. The
Commission’s notice of investigation
named as respondents BMC Medical
Co., Ltd. of Beijing, China; 3B Medical,
Inc. of Lake Wales, Florida; and 3B
Products, L.L.C. of Lake Wales, Florida
(collective, ‘‘the Respondents’’). A
Commission investigative attorney
(‘‘IA’’) is also participating in this
investigation.
On October 30, 2013, Complainants
filed an unopposed motion to amend
the Complaint to correct an error in its
allegations regarding the domestic
industry. The motion stated that neither
the Respondents nor the IA opposed the
motion to amend. On November 21,
2013, the ALJ issued an ID, finding good
cause shown and granting
Complainants’ motion. There were no
petitions for review.
Having considered the ID, the
Commission has determined not to
review the subject ID.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and § 210.42 of the Commission’s Rules
E:\FR\FM\19DEN1.SGM
19DEN1
Federal Register / Vol. 78, No. 244 / Thursday, December 19, 2013 / Notices
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
of Practice and Procedure (19 CFR
210.42).
By order of the Commission.
Issued: December 13, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–30115 Filed 12–18–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Bureau of Alcohol, Tobacco, Firearms
and Explosives
[OMB Number 1140–0017]
Agency Information Collection
Activities; Proposed Collection;
Comments Requested: Annual
Firearms Manufacturing and
Exportation Report Under United
States Code, Firearms
emcdonald on DSK67QTVN1PROD with NOTICES
ACTION:
60-Day notice.
The Department of Justice (DOJ),
Bureau of Alcohol, Tobacco, Firearms
and Explosives (ATF), will submit the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection is published to
obtain comments from the public and
affected agencies. Comments are
encouraged and will be accepted for
‘‘sixty days’’ until February 18, 2014.
This process is conducted in accordance
with 5 CFR 1320.10.
If you have comments especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Thomas DiDomenico,
Firearms and Explosives Services
Division at AFMERQuestions@atf.gov.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
VerDate Mar<15>2010
16:41 Dec 18, 2013
Jkt 232001
76859
DEPARTMENT OF JUSTICE
Summary of Information Collection
The Department of Justice (DOJ),
Bureau of Alcohol, Tobacco, Firearms
and Explosives (ATF), will submit the
following information collection request
to the Office of Management and Budget
(OMB) for review and clearance in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection is published to
obtain comments from the public and
affected agencies. Comments are
encouraged and will be accepted for
‘‘sixty days’’ until February 18, 2014.
This process is conducted in accordance
with 5 CFR 1320.10.
If you have comments especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Joseph Fox, Branch Chief,
Alcohol and Tobacco Enforcement
Branch, Bureau of Alcohol, Tobacco,
Firearms and Explosives at Joseph.Fox@
atf.gov.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Annual Firearms Manufacturing and
Exportation Report under 18 U.S.C.
Chapter 44, Firearms.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: ATF F
5300.11. Bureau of Alcohol, Tobacco,
Firearms and Explosives.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Business or other forprofit. Other: Federal Government,
State, Local, or Tribal Government.
Need for Collection
ATF collects this data for the purpose
of witness qualifications, congressional
investigations, court decision and
disclosure and furnishing information to
other Federal agencies.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 8,500
respondents will complete a 20 minute
form.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 2,833
annual total burden hours associated
with this collection.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Two Constitution
Square, 145 N Street NE., Room 3W–
1407B, Washington, DC 20530.
Dated: December 13, 2013.
Jerri Murray,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2013–30153 Filed 12–18–13; 8:45 am]
BILLING CODE 4410–FY–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Bureau of Alcohol, Tobacco, Firearms
and Explosives
[OMB Number 1140–0098]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested: Prevent All
Cigarette Trafficking (PACT) Act
Registration Form
ACTION:
E:\FR\FM\19DEN1.SGM
60-Day notice.
19DEN1
Agencies
[Federal Register Volume 78, Number 244 (Thursday, December 19, 2013)]
[Notices]
[Pages 76858-76859]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-30115]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-890]
Certain Sleep-Disordered Breathing Treatment Systems and
Components Thereof; Commission Determination Not To Review an Initial
Determination Granting an Unopposed Motion of Complainants Resmed
Corp., Resmed Inc., and Resmed Ltd. To Amend the Complaint
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined not to review an initial determination
(``ID'') (Order No. 4) of the presiding administrative law judge
granting an unopposed motion of complainants Resmed Corp., Resmed Inc.,
and Resmed Ltd. to amend the complaint in the above-captioned
investigation.
FOR FURTHER INFORMATION CONTACT: James A. Worth, Office of the General
Counsel, U.S. International Trade Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202) 205-3065. Copies of non-
confidential documents filed in connection with this investigation are
or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW., Washington, DC 20436,
telephone (202) 205-2000. General information concerning the Commission
may also be obtained by accessing its Internet server (https://www.usitc.gov). The public record for this investigation may be viewed
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised that information on this matter
can be obtained by contacting the Commission's TDD terminal on (202)
205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on Friday, August 23, 2013, based on a complaint filed on July 19,
2013, on behalf of ResMed Corp. of San Diego, California; ResMed Inc.
of San Diego, California; and ResMed Ltd. of Bella Vista, Australia
(collectively, ``Complainants''). 78 FR 52563 (August 23, 2013). The
complaint alleged violations of Section 337 of the Tariff Act of 1930,
as amended, 19 U.S.C. 1337, in the sale for importation, importation,
or sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof by reason
of infringement of one or more of claims 32-37, 53, 79, 80, and 88 of
U.S. Patent No. 7,997,267; claims 1-7 of U.S. Patent No. 7,614,398;
claim 1 of U.S. Patent No. 7,938,116; claims 30, 37, and 38 of U.S.
Patent No. 7,341,060; claims 1, 3, 5, 11, 28, 30, 31, and 56 of U.S.
Patent No. 8,312,883; claims 13, 15, 16, 26-28, 51, 52, and 55 of U.S.
Patent No. 7,926,487; claims 1, 3, 6, 7, 9, 29, 32, 35, 40, 42, 45, 50,
51, 56, 59, 89, 92, 94, and 96 of U.S. Patent No. 7,178,527; and claims
19-24, 26, 29-36, and 39-41 of U.S. Patent No. 7,950,392. The
Commission's notice of investigation named as respondents BMC Medical
Co., Ltd. of Beijing, China; 3B Medical, Inc. of Lake Wales, Florida;
and 3B Products, L.L.C. of Lake Wales, Florida (collective, ``the
Respondents''). A Commission investigative attorney (``IA'') is also
participating in this investigation.
On October 30, 2013, Complainants filed an unopposed motion to
amend the Complaint to correct an error in its allegations regarding
the domestic industry. The motion stated that neither the Respondents
nor the IA opposed the motion to amend. On November 21, 2013, the ALJ
issued an ID, finding good cause shown and granting Complainants'
motion. There were no petitions for review.
Having considered the ID, the Commission has determined not to
review the subject ID.
This action is taken under the authority of section 337 of the
Tariff Act of 1930, as amended (19 U.S.C. 1337), and Sec. 210.42 of
the Commission's Rules
[[Page 76859]]
of Practice and Procedure (19 CFR 210.42).
By order of the Commission.
Issued: December 13, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-30115 Filed 12-18-13; 8:45 am]
BILLING CODE 7020-02-P